ResMed Price PerformanceShares of ResMed stock traded up $0.11 during trading hours on Thursday, reaching $257.83. Following the completion of the sale, the director owned 66,773 shares in the company, valued at approximately $16,615,125.59. Also, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Wednesday, January 7th. Giverny Capital Inc. purchased a new position in ResMed in the third quarter valued at approximately $64,441,000. According to MarketBeat, ResMed presently has an average rating of “Moderate Buy” and an average target price of $296.09.